FGEN - FibroGen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
50.67
+1.56 (+3.18%)
At close: 4:00PM EST

50.67 0.00 (0.00%)
After hours: 5:02PM EST

Stock chart is not supported by your current browser
Previous Close49.11
Open49.22
Bid50.25 x 900
Ask62.00 x 1300
Day's Range49.22 - 50.80
52 Week Range37.27 - 68.55
Volume590,609
Avg. Volume695,253
Market Cap4.306B
Beta (3Y Monthly)2.67
PE Ratio (TTM)N/A
EPS (TTM)-1.76
Earnings DateFeb 25, 2019 - Mar 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est71.00
Trade prices are not sourced from all markets
  • Markit8 days ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    # FibroGen Inc ### NASDAQ/NGS:FGEN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding FGEN is favorable, with net inflows of $5.19 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Can This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes
    Investor's Business Daily27 days ago

    Can This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes

    Fibrogen stock popped Thursday on results of clinical studies showing that its AstraZeneca-partnered anemia treatment in kidney disease patients could rival Amgen's.

  • The Wall Street Journal27 days ago

    [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time

    China has for the first time approved a treatment from a global drugmaker before any other country, illustrating its recent push to bring in cutting-edge medicines—as well as Western companies’ growing interest in the market. China approved 30 innovative drugs from foreign developers in the first nine months of this year—some taking just weeks—and, according to consulting firm McKinsey & Co., is on track to at least match last year’s 40 approvals, which marked the most by the regulator in any single year for at least a decade. In 2016, China approved three such foreign drugs.

  • MarketWatch27 days ago

    AstraZeneca stock up 2.8% after announcing EU approval of COPD treatment

    Shares of AstraZeneca Plc were up 2.8% in premarket trade Thursday after the company announced its inhaler Bevespi Aerosphere was approved by the European Commission as a treatment for symptoms of chronic obstructive pulmonary disease (COPD). The inhaler is already available to COPD patients in the U.S. Earlier on Thursday, the company announced that two major Phase 3 trials of roxadustat, a potential treatment for anemic patients with chronic kidney disease being developed with FibroGen, Inc. , had met their primary endpoints. Shares of AstroZeneca have gained 18% in the year to date, while the S&P 500 has fallen 6%.

  • Markit28 days ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    # FibroGen Inc ### NASDAQ/NGS:FGEN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding FGEN are favorable, with net inflows of $1.79 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire28 days ago

    FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease

    FibroGen, Inc. (FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI), met all primary efficacy endpoints in the three global pivotal Phase 3 trials conducted by FibroGen: ANDES in non-dialysis-dependent (NDD) chronic kidney disease (CKD) patients, HIMALAYAS in incident (newly initiated) dialysis patients, and SIERRAS in dialysis-dependent (DD) CKD patients. “Anemia in CKD is a serious condition for which a significant number of patients are left without treatment options in many markets,” said Thomas B. Neff, Chief Executive Officer, FibroGen.

  • ACCESSWIRE28 days ago

    Today's Research Reports on Trending Tickers: Aimmune Therapeutics and FibroGen

    NEW YORK, NY / ACCESSWIRE / December 20, 2018 / U.S. equities closed down on Wednesday as the anticipated interest rate increase was confirmed by the Federal Reserve, following Chairman Jerome Powell’s ...

  • FibroGen Inc (FGEN): Hedge Fund Sentiment Unchanged
    Insider Monkey29 days ago

    FibroGen Inc (FGEN): Hedge Fund Sentiment Unchanged

    Before we spend days researching a stock idea we’d like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 8.7% through October 26th. Forty percent of the S&P 500 constituents were down more than 10%. The average return of a randomly picked stock […]

  • Why a kidney disease drug approval in China is just the start for this S.F. company
    American City Business Journals29 days ago

    Why a kidney disease drug approval in China is just the start for this S.F. company

    After 25 years, FibroGen won its first drug approval, a treatment for anemia in chronic kidney disease patients in China. It hopes to follow that up with approvals in the United States, Japan and Europe over the next year.

  • Benzingalast month

    The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 17) Endocyte, Inc. (NASDAQ: ECYT ) Down In The Dumps (Biotech ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Puma Biotechnology and FibroGen

    NEW YORK, NY / ACCESSWIRE / December 18, 2018 / U.S. equities extended losses on Monday as investors await details from the Federal Reserve's final policy meeting of 2018 on Wednesday. The Dow Jones Industrial ...

  • Reuterslast month

    China first to approve AstraZeneca, FibroGen anaemia drug

    China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe. Despite the early win, the two partners said on Tuesday they did not expect to launch roxadustat in China until the second half of 2019. FibroGen sponsored the development and registration of roxadustat in China, while AstraZeneca is responsible for marketing the medicine.

  • Reuterslast month

    China first to approve AstraZeneca, FibroGen anaemia drug

    China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe. Despite the early win, the two partners said on Tuesday they did not expect to launch roxadustat in China until the second half of 2019. FibroGen sponsored the development and registration of roxadustat in China, while AstraZeneca is responsible for marketing the medicine.

  • GlobeNewswirelast month

    FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

    FibroGen, Inc. (FGEN) today announced that FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorization from the National Medical Products Administration (NMPA) for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of patients with anemia caused by chronic kidney disease (CKD) in patients who are dialysis-dependent (DD). The medicine can be prescribed to patients who use hemodialysis or peritoneal dialysis.

  • Simply Wall St.last month

    How Many Insiders Sold FibroGen, Inc. (NASDAQ:FGEN) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about FibroGen Inc.

    FibroGen Inc NASDAQ/NGS:FGEN

  • GlobeNewswirelast month

    FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors

    “We are delighted to welcome Dr. Maykin Ho, an accomplished leader with a great breadth of knowledge in the biotechnology industry, as a new Board member,” said Thomas B. Neff, CEO. Dr. Ho has more than 30 years of experience in the healthcare and finance industries.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $227 million over the last one-month into ETFs that hold FGEN are among the lowest of the last year and appear to be slowing.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FGEN earnings conference call or presentation 8-Nov-18 10:00pm GMT

    Q3 2018 FibroGen Inc Earnings Call

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen

    NEW YORK, NY / ACCESSWIRE / November 14, 2018 / U.S. equities saw losses on Tuesday as continued weakness in oil prices pressured energy stocks lower. Crude oil dropped for the 12th consecutive session, ...

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold FGEN had net inflows of $1.75 billion over the last one-month.

  • FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
    Zacks2 months ago

    FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates

    FibroGen (FGEN) delivered earnings and revenue surprises of -42.86% and -37.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    FibroGen: 3Q Earnings Snapshot

    The San Francisco-based company said it had a loss of 50 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    FibroGen Reports Third Quarter 2018 Financial Results

    —Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today.